Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Pal-AHK vs Pentapeptide-18

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Pal-AHK and Pentapeptide-18 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Pentapeptide-18 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Pentapeptide-18's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Pal-AHK

Cosmetic Clinical Studies

Pentapeptide-18

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Pal-AHK Pentapeptide-18
Class Cosmetic lipopeptide (hair) Cosmetic peptide; enkephalin mimetic
Drug class Dermatologic Dermatologic
Mechanism Palmitoyl-modified AHK for enhanced skin/scalp penetration; angiogenic signaling Enkephalin mimetic; modulates SNAP-25 at muscle-neuron interface (topical)
Route Topical Topical
Half-life Topical Topical
Dosage (research) Topical 0.1-1% Topical 2-10%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 2 indexed (PubMed 0 · CT 0 · EPMC 2) 11 indexed (PubMed 6 · CT 0 · EPMC 5)
Availability Cosmetic Cosmetic
Reported risks Minimal Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Pal-AHK or Pentapeptide-18?

Pal-AHK and Pentapeptide-18 share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Pentapeptide-18 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Pentapeptide-18's evidence base is currently denser.

What is the difference between Pal-AHK and Pentapeptide-18?

Pal-AHK is classed as Cosmetic lipopeptide (hair); Pentapeptide-18 is classed as Cosmetic peptide; enkephalin mimetic. Reported mechanism: Pal-AHK, Palmitoyl-modified AHK for enhanced skin/scalp penetration; angiogenic signaling; Pentapeptide-18, Enkephalin mimetic; modulates SNAP-25 at muscle-neuron interface (topical). Reported half-life: Pal-AHK, Topical; Pentapeptide-18, Topical. Routes in published studies: Pal-AHK, Topical; Pentapeptide-18, Topical.

Which has stronger evidence, Pal-AHK or Pentapeptide-18?

Pal-AHK and Pentapeptide-18 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Pal-AHK is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 2 indexed studies. Pentapeptide-18 is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 11 indexed studies.

Which is more accessible, Pal-AHK or Pentapeptide-18?

Neither Pal-AHK nor Pentapeptide-18 is an FDA-approved drug. Catalog status: Pal-AHK, Cosmetic; Pentapeptide-18, Cosmetic.

Are Pal-AHK and Pentapeptide-18 ever combined?

Pal-AHK and Pentapeptide-18 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…